RxDoctor Payments Data

Cristina Terrizzano, PA

Physician Assistant · Stanford, CANPI 1811561566

Payments from drug & device makers

$834in general payments, 2019–2025

Across 29 payments — averaging $28.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$201
  • Urogen Pharma, Inc.$96
  • Astellas Pharma US Inc$94
  • AbbVie$92
  • Johnson & Johnson$91
  • Agiliti Surgical, Inc.$73
  • plus $187 from 8 others

What the payments were for

  • Food & beverage$834100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sumitomo Pharma America, Inc.6$201
Urogen Pharma, Inc.3$96
Astellas Pharma US Inc3$94
AbbVie4$92
Johnson & Johnson4$91
Agiliti Surgical, Inc.1$73
Immunitybio, Inc.1$34
180 Medical, Inc.1$29
Axonics, Inc.1$24
Bayer1$22
Myriad Genetic Laboratories, Inc.1$21
Pfizer1$21
Medtronic1$20
Progenics Pharmaceuticals, Inc.1$17

How this compares

$834 in reported general payments places this provider in the 70th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$5,707
Medicare patients
48
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron73$59,561
MyrbetriqMirabegron17$18,296
Estradiol33$3,145
Tamsulosin Hcl80$1,393
Cephalexin95$979
Finasteride40$699
Oxybutynin Chloride ErOxybutynin Chloride15$624
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst55$611
Fluconazole11$197
Ciprofloxacin Hcl29$139
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$99
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$201$59,56173 claims
Astellas Pharma US IncMyrbetriq$94$18,29617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →